Literature DB >> 29850194

Is the door open to further investigation with antiangiogenesis in SCLC?

Marcello Tiseo1, Luca Boni2, Andrea Ardizzoni3.   

Abstract

Entities:  

Year:  2018        PMID： 29850194      PMCID： PMC5949433          DOI： 10.21037/jtd.2018.03.87

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Another disappointing result, but how good is it?

Authors:  Yasushi Goto
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Elusive Target of Angiogenesis in Small-Cell Lung Cancer.

Authors:  Joel W Neal; Heather A Wakelee
Journal:  J Clin Oncol       Date:  2017-02-06       Impact factor: 44.544

3.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Authors:  Lee M Ellis; David S Bernstein; Emile E Voest; Jordan D Berlin; Daniel Sargent; Patricia Cortazar; Elizabeth Garrett-Mayer; Roy S Herbst; Rogerio C Lilenbaum; Camelia Sima; Alan P Venook; Mithat Gonen; Richard L Schilsky; Neal J Meropol; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

4.  Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

Authors:  Marcello Tiseo; Luca Boni; Francesca Ambrosio; Andrea Camerini; Editta Baldini; Saverio Cinieri; Matteo Brighenti; Francesca Zanelli; Efisio Defraia; Rita Chiari; Claudio Dazzi; Carmelo Tibaldi; Gianni Michele Turolla; Vito D'Alessandro; Nicoletta Zilembo; Anna Rita Trolese; Francesco Grossi; Ferdinando Riccardi; Andrea Ardizzoni
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

5.  Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Authors:  Neal E Ready; Herbert H Pang; Lin Gu; Gregory A Otterson; Sachdev P Thomas; Antonius A Miller; Maria Baggstrom; Gregory A Masters; Stephen L Graziano; Jeffrey Crawford; Jeffrey Bogart; Everett E Vokes
Journal:  J Clin Oncol       Date:  2015-03-02       Impact factor: 44.544

6.  Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.

Authors:  David R Spigel; Peter M Townley; David M Waterhouse; Liang Fang; Ibrahim Adiguzel; Jane E Huang; David A Karlin; Leonardo Faoro; Frank A Scappaticci; Mark A Socinski
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

Review 7.  The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Authors:  Christian Manegold; Anne-Marie C Dingemans; Jhanelle E Gray; Kazuhiko Nakagawa; Marianne Nicolson; Solange Peters; Martin Reck; Yi-Long Wu; Odd Terje Brustugun; Lucio Crinò; Enriqueta Felip; Dean Fennell; Pilar Garrido; Rudolf M Huber; Aurélien Marabelle; Marcin Moniuszko; Françoise Mornex; Silvia Novello; Mauro Papotti; Maurice Pérol; Egbert F Smit; Kostas Syrigos; Jan P van Meerbeeck; Nico van Zandwijk; James Chih-Hsin Yang; Caicun Zhou; Everett Vokes
Journal:  J Thorac Oncol       Date:  2016-10-08       Impact factor: 15.609

8.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.